The SWOG 9346 [A9346] trial sought to compare subsequent "health events" in men receiving Goserelin (Zoladex) + Bicalutamide (Casodex) continuously (ADT) versus intermittently (IADT).
"... induction therapy ... for 7 months. If the PSA level declined to <4.0 ng/mL, patients were randomized to either continuous or intermittent ADT."
They identified a subgroup (636) of men who had no other insurance than Medicare, & somehow obtained Medicare claim information.
It might not surprise some that 24% of the ADT arm suffered "ischemic and thrombotic events" during the 10 year follow-up, but it will stun many that 33% of the IADT arm had similar events. IADT is supposed to improve quality of life over ADT - not compromise it.
The study was published in January [1]
The latest Urology Times issue contains more info & a possible explanation [2]:
Cycling of coag. cascade may increase risk.
“One might ask, why would ischemic-thrombotic events be lower for patients on continuous ADT? We know there is an increased risk of diabetes and certain cardiovascular diseases with any exposure to ADT. Consulting with my hematology colleagues, they pointed out that the cycling of the coagulation cascade may increase risk, as it does for women on hormone replacement therapy or on birth control pills. The risk is highest in the first 6 months, after initiation of ADT. So, it may increase with each initiation of treatment,” Dr. Hershman said."
In other words, the transition to ADT creates a spike in clotting risk, & IADT has multiple transitions - therefore more cumulative risk.
{The 5-year experience of ischemic and thrombotic events was 14% for ADT, but 25% for IADT. For ischemic events alone: 5-years = 4% & 9%; 10-years = 7% & 12% - for ADT & IADT, respectively.}
The take-home message that professionals are coming away with is that IADT is unsafe. My feeling is that more should be done to control coagulation.
My GP told me that there are no prophylactic drugs to reduce clotting risk. Warfarin is prescribed only after an event - assuming one survives the event. Two such events & one becomes a warfarin lifer. Under these circumstances, warfarin is considered to be the lesser of two evils - it is a dangerous drug & people die because of it.
I have posted about the need to monitor coagulation factors, & the possibility of controlling them via nattokinase & anti-inflammatories. This study is a wake-up call. The percentages are too high, & continuous ADT is not the answer. In the absence of risk-reduction drugs, one must take control.
-Patrick